Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply

Affiliations

¹ Department of Oncology, University of Cambridge, Cambridge CB2 0QQ, UK. Electronic address: cec50@cam.ac.uk.
² Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK.
³ Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK.

Comment

Charlotte E Coles et al. Lancet. 2024.

. 2024 May 4;403(10438):1752.

doi: 10.1016/S0140-6736(24)00353-2.

¹ Department of Oncology, University of Cambridge, Cambridge CB2 0QQ, UK. Electronic address: cec50@cam.ac.uk.
² Clinical Trials and Statistics Unit, Institute of Cancer Research, Sutton, UK.
³ Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, UK.

No abstract available

Comment on

Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Zhao D, Li Y, Qu Y, He C, Lu Y. Zhao D, et al. Lancet. 2024 May 4;403(10438):1749. doi: 10.1016/S0140-6736(24)00354-4. Lancet. 2024. PMID: 38704166 No abstract available.
Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Mizumoto M, Oshiro Y, Sakurai H. Mizumoto M, et al. Lancet. 2024 May 4;403(10438):1749-1750. doi: 10.1016/S0140-6736(24)00358-1. Lancet. 2024. PMID: 38704167 No abstract available.
Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Guinot JL, Gutierrez C, Hannoun-Levi JM. Guinot JL, et al. Lancet. 2024 May 4;403(10438):1750-1751. doi: 10.1016/S0140-6736(24)00356-8. Lancet. 2024. PMID: 38704168 No abstract available.
Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Mulliez T, De Ridder M. Mulliez T, et al. Lancet. 2024 May 4;403(10438):1751. doi: 10.1016/S0140-6736(24)00355-6. Lancet. 2024. PMID: 38704169 No abstract available.
Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
Gregucci F, Ciabattoni A. Gregucci F, et al. Lancet. 2024 May 4;403(10438):1751-1752. doi: 10.1016/S0140-6736(24)00357-X. Lancet. 2024. PMID: 38704170 No abstract available.